MedTrace Logo

SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT04676607 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-06-13

No results posted yet for this study

Summary

This trial aims to prospectively assess the safety and efficiency of SHR7390 in metastatic castration-resistant prostate cancer

Conditions

Interventions

DRUG

SHR7390

SHR7390

Sponsors & Collaborators

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    lead OTHER

Principal Investigators

  • Hongqian Guo · Department of Urology, Drum Tower Hospital, Medical School of Nanjing University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-17
Primary Completion
2023-06-12
Completion
2023-06-12

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04676607 on ClinicalTrials.gov